Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | EIF4E | P06730 | 2/20 | 0.48 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | MDM4 | O15151 | 4/20 | 0.47 |
| ▸ | PRKAR2A | P13861 | 8/20 | 0.46 |
| ▸ | PRKAR2B | P31323 | 6/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155284 | 0.81 | TNFSF11 (0.38) | ESR1 | |
| SCHEMBL24155488 | 0.81 | CXCR4 (0.40) | — | |
| SCHEMBL24155481 | 0.80 | TNFSF11 (0.37) | ESR1 | |
| SCHEMBL24155857 | 0.67 | VDR (0.45) | ESR1 | |
| SCHEMBL23295836 | 0.63 | WDR5 (0.55) | ESR1EIF4EEIF4EBP1MDM2MDM4 | |
| SCHEMBL17880430 | 0.62 | MDM2 (0.78) | ESR1EIF4EEIF4EBP1MDM2MDM4 | |
| SCHEMBL20563805 | 0.62 | WDR5 (0.56) | ESR1EIF4EEIF4EBP1MDM2MDM4 | |
| SCHEMBL20564489 | 0.62 | WDR5 (0.75) | ESR1EIF4EEIF4EBP1MDM2MDM4 | |
| SCHEMBL15005758 | 0.62 | WDR5 (0.78) | EIF4EEIF4EBP1MDM2MDM4 | |
| SCHEMBL23682876 | 0.62 | WDR5 (0.78) | EIF4EEIF4EBP1MDM2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VITEK, MICHAEL PETER | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VIP, NPPA, IAPP | ESR1 3999/4885EIF4E 3230/4885EIF4EBP1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.